Corbenic Partners’s GoodRx Holdings GDRX Stock Holding History

Corbenic Partners’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-129	Closed	-$4K	–	250
2021 Q4	$4K	Buy	+129	New	+$5.19K	﹤0.01%	221

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

DIG

Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return

RRCP

Rip Road Capital Partners Boston, Massachusetts $62.5M AUM 1.22% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Corbenic Partners's GDRX Position: Q1 2022 in Review

Corbenic Partners sold out of GoodRx Holdings (GDRX) in Q1 2022, closing a stake of 129 shares — an estimated $4K sold.

Corbenic Partners first reported a position in GDRX in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 167 funds tracked by Wall St. Rank hold GDRX as of Q1 2022.

Corbenic Partners reported no remaining GoodRx Holdings position as of Q1 2022 after selling out during the quarter.
Corbenic Partners sold 129 GoodRx Holdings shares in Q1 2022, an estimated $4K.
Corbenic Partners first reported a position in GoodRx Holdings in Q4 2021 and held it in 1 quarter.
Corbenic Partners's GoodRx Holdings position peaked at $4K in Q4 2021.
167 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2022.

Based on Corbenic Partners's 13F filing for Q1 2022, filed 14 Apr 2022.